Cemiplimab for Secondary Angiosarcomas

Exclusion criteria

• . Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for irAEs. The following are not exclusionary: vitiligo, childhood asthma that has resolved, type 1 Diabetes mellitus, residual hypothyroidism that required only hormone therapy, or psoriasis that does not require systematic treatment.
• . Prior treatment with immune checkpoint inhibitors.
• . Continuous immunosuppressive corticosteroid treatment (doses \> 10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of cemiplimab. Note: patients who require a brief course of steroids (e.g. as prophylaxis for imaging studies) are not excluded.
• . Active uncontrolled infection requiring therapy, including infection with HIV, active infection with HBV or HCV.
• . History of pneumonitis within the last 5 years.
• . Untreated brain metastasis(es) that may be considered active.
• . Patients with allergy or hypersensitivity to cemiplimab or to any of the excipients must be excluded. Specifically, because of the presence of trace components in cemiplimab, patients with allergy or hypersensitivity to doxycycline or tetracycline are excluded.
• . History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments